QIAGEN (QGEN)
(Delayed Data from NYSE)
$45.59 USD
-0.09 (-0.20%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Income Statements
Fiscal Year end for QIAGEN NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,965 | 2,142 | 2,252 | 1,870 | 1,526 |
Cost Of Goods | 732 | 757 | 801 | 638 | 521 |
Gross Profit | 1,234 | 1,385 | 1,451 | 1,233 | 1,005 |
Selling & Adminstrative & Depr. & Amort Expenses | 824 | 853 | 821 | 846 | 1,031 |
Income After Depreciation & Amortization | 410 | 531 | 630 | 386 | -26 |
Non-Operating Income | 73 | 40 | 50 | 124 | 23 |
Interest Expense | 53 | 58 | 54 | 71 | 74 |
Pretax Income | 430 | 513 | 626 | 439 | -78 |
Income Taxes | 89 | 89 | 113 | 80 | -36 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 341 | 423 | 513 | 359 | -41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 341 | 423 | 513 | 359 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 645 | 774 | 877 | 634 | 246 |
Depreciation & Amortization (Cash Flow) | 236 | 242 | 247 | 247 | 272 |
Income After Depreciation & Amortization | 410 | 531 | 630 | 386 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 230.62 | 223.23 | 225.07 | 227.19 | 225.45 |
Diluted EPS Before Non-Recurring Items | 2.07 | 2.45 | 2.73 | 2.22 | 1.47 |
Diluted Net EPS (GAAP) | 1.48 | 1.90 | 2.28 | 1.58 | -0.19 |
Fiscal Year end for QIAGEN NV falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 496.35 | 458.80 | 509.16 | 475.89 | 494.86 |
Cost Of Goods | 461.58 | 167.81 | 193.06 | 177.93 | 182.71 |
Gross Profit | 34.76 | 290.99 | 316.10 | 297.96 | 312.15 |
SG&A, R&D, and Dept/Amort Expenses | 263.20 | 196.04 | 205.49 | 200.78 | 206.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | -228.44 | 94.95 | 110.61 | 97.18 | 105.43 |
Non-Operating Income | 15.91 | 17.64 | 20.70 | 15.67 | 10.38 |
Interest Expense | 10.92 | 10.29 | 12.44 | 13.02 | 13.50 |
Pretax Income | -223.45 | 102.29 | 118.88 | 99.83 | 102.32 |
Income Taxes | -39.99 | 21.62 | 21.21 | 22.01 | 21.53 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -183.46 | 80.67 | 97.66 | 77.82 | 80.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -183.46 | 80.67 | 97.66 | 77.82 | 80.79 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 224.02 | 226.57 | 230.75 | 223.70 | 223.60 |
Diluted EPS Before Non-Recurring Items | 0.55 | 0.46 | 0.55 | 0.52 | 0.53 |
Diluted Net EPS (GAAP) | -0.83 | 0.36 | 0.39 | 0.35 | 0.36 |